Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease

The catechol O-methyltransferase inhibitor entacapone acts by extending the elimination half-life of levodopa and is currently approved as an adjunct to levodopa for the treatment of patients with Parkinson disease (PD) with motor fluctuations. To determine if the addition of entacapone administrati...

Full description

Saved in:

Bibliographic Details
Published in:	Archives of neurology (Chicago) Vol. 61; no. 10; p. 1563
Main Authors:	Olanow, C W, Kieburtz, K, Stern, M, Watts, R, Langston, J W, Guarnieri, M, Hubble, J
Format:	Journal Article
Language:	English
Published:	United States 01-10-2004
Subjects:	Aged Analysis of Variance Antiparkinson Agents - therapeutic use Catechol O-Methyltransferase Inhibitors Catechols - therapeutic use Double-Blind Method Drug Synergism Drug Therapy, Combination Female Humans Levodopa - therapeutic use Male Middle Aged Motor Activity - drug effects Nitriles Parkinson Disease - drug therapy Prospective Studies Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The catechol O-methyltransferase inhibitor entacapone acts by extending the elimination half-life of levodopa and is currently approved as an adjunct to levodopa for the treatment of patients with Parkinson disease (PD) with motor fluctuations. To determine if the addition of entacapone administration provides benefit to levodopa-treated PD patients who have a stable response to levodopa and do not experience motor complications. Prospective, double-blind, placebo-controlled trial. Outpatient multicenter study. Female and male patients 30 years or older with idiopathic PD receiving stable doses of levodopa or carbidopa with or without other dopaminergic therapies and who did not experience motor fluctuations were eligible for the study. Parkinsonian function and quality of life. The addition of entacapone did not improve motor scores on the Unified Parkinson's Disease Rating Scale in levodopa-treated PD patients who did not experience motor fluctuations. The mean +/- SE adjusted change between baseline and final treatment visit was -0.9 +/- 0.35 in the entacapone group and -0.8 +/- 0.35 in the placebo group (P = .83). Significant improvement with entacapone treatment was detected in several quality-of-life measures, including the Parkinson Disease Questionnaire 39, the 36-item Short-Form Health Survey, the Parkinson's Symptom Inventory, and investigator and subject Clinical Global Assessments. The drug was well tolerated by patients in this population. The catechol O-methyltransferase inhibitor entacapone, used as an adjunct to levodopa in PD patients who do not experience motor fluctuations, does not improve Unified Parkinson's Disease Rating Scale motor scores but does improve a variety of quality-of-life measures.
ISSN:	0003-9942
DOI:	10.1001/archneur.61.10.1563